(Q56060521)

https://api.crossref.org/works/10.2146%2FAJHP050514

Major histocompatibility complex-directed susceptibility to rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: results from the Iowa Women's Health Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Clinical utility of the anti-CCP assay in patients with rheumatic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Therapeutic strategies for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Guidelines for the management of rheumatoid arthritis: 2002 Update

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Anti-inflammatory drugs and their mechanism of action

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Prophylaxis and treatment of non-steroidal anti-inflammatory drug-induced upper gastrointestinal side-effects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

The clinical significance of inhibition of renal prostaglandin synthesis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Effects of NSAIDs on the incidence of hospitalisations for renal dysfunction in users of ACE inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

The Effect of Glucocorticoids on Joint Destruction in Rheumatoid Arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Glucocorticoid-induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Prevention of glucocorticoid-induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

How to prevent steroid induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Differential Control of Cell Cycle, Proliferation, and Survival of Primary T Lymphocytes by Purine and Pyrimidine Nucleotides

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Relative bioavailability of oral low dose methotrexate. A comparison of 2 different formulations

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Membrane transport of folates

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

HPLC Determination of Erythrocyte Methotrexate Polyglutamates after Low-Dose Methotrexate Therapy in Patients with Rheumatoid Arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A twenty-four-week controlled clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Refractory nephrotic syndrome in lupus nephritis: favorable response to indomethacin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Sulphasalazine inhibition of human granulocyte activation by inhibition of second messenger compounds

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Sulphasalazine versus penicillamine in the treatment of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

New drugs for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Clinical pharmacokinetics of leflunomide

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Aspirin could be used to prevent cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

The early history of antirheumatic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Synergistic inhibition of human B cell activation by gold sodium thiomalate and auranofin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Gold salts in the treatment of rheumatoid arthritis. A double-blind study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Tetracyclines, molecular and clinical aspects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Clinical pharmacokinetics of TNF antagonists: how do they differ?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

The pharmacokinetics of etanercept in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Listeria meningitis after treatment with infliximab

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Infections in patients with rheumatoid arthritis treated with biologic agents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

A signal achievement in the treatment of arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

New therapies for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050514